Thanks, third highlights year conference our fiscal review XXXX. and our to of Welcome, call the fiscal quarter operating results Jordyn. everyone, to
Joining Financial Pete of discuss Intellectual Vice Conley, our is me and our Senior today who Officer results. Chief Property, President financial will
of of Being our investors today I'm we've goals work progress and articulated and our going transparent call. we've walk XXXX. our to preview balance of date, earnings our against critical previous overview communication year to streams for proud is through established our you I'll in fiscal followers. I'll provide the channels with us, progress the for an the and I'm
are subscribe addition out and through to to following us every time encourage a releases, newsletter distributed our to our In I reach occurs, our to you press event ask@knowlabs.co e-mail our on material which website.
visit validation our as and www.knowlabs.co website also research constantly website, This access progress we are should clinical our You data our of web our page. provides our from section trials. to updating and
the terms We of data have raised significantly in transparency. bar
has to the by core acceleration A by Chief and responsibilities. our XX, Chairman January Board. progress I development year, discussion today's of the was Directors and leadership Officer On team major some while Board execution. of XXXX. of operational start added to revisiting redistributed named executive like an We Executive our as happened changes the in company's I'd lot calendar and continuing members of new with significant events starting this
long be meaningful months. past sensor we in These technology, partners We list and X achieved the as very have milestones data affairs of support science, and existing product strategic to a regulatory changes design team. to the Know new disclosed Labs proven in effective
development of Bio-RFID testing allows to device to our the lab. X In we research device data device. in scale we if for technology. the This a X including data lab device. often designed team Generation tenfold, It's is the be scenarios, powerful this important our our collection to June, Gen both diverse a and We're proprietary The revealed take stage inside device we approval. portable across collection asked FDA will our more participant is and when submit outside technology an our populations
Generation This is X.
we'll next regarding from learned We what cannot what generation the today generation version will we the refine on for will FDA clearance. speculate X. We that the device take Generation to be based
the glucose to approval In collection, of That billion terms are received obtain performance must being broad sensor every on and improve generalizable. repeatability protocols, in we X features. and data testing in development day. has what work with points. than sets test enough and collection is parallel stability, a data to perform results are Bio-RFID months, clinical run in our IRB last which our research that resulted we population X Multiple of which data X-hour testing team the more XXX, have and collected almost Ultimately,
X Scientific the validation development manuscripts X medical technology. published the months, our and is In at X conferences. last posters presented have of we for critical
Spectral The XXXX - Mayo Summit. for Solutions and at presented collaboration Unique Physiologic Implications Physiological in first titled was poster Non-Invasive Detecting Monitoring American Clinic was in the with Analyte-Specific Responses Radio Frequency conducted Liquid Society
accuracy Know different a tests. XXX% Labs' accuracy analytes rate study these of sensor proprietary quantifying demonstrated in in vitro, Bio-RFID in proving This the
Glucose "Technical Clinical Throughout publications and the and Meeting. Feasibility The improve titled, at Compared presented of Annual GX," we've a Dexcom second Endocrinology presentations, Novel American Association accuracy, was to been Sensor these stability for poster Monitoring repeatability. to XXXX of able Non-Invasive Bio-RFID's Blood
delivering similar which a FDA-cleared in XX.X%, devices we closer MARD an of of range MARD, with XX.X% to device much to under a and our a to from MARD goal accuracy us other positions a MARD it, a call Going XX%.
we intellectual XX% than property On just X in the months. our more front, by portfolio grew
pending XXXX. patents the have we patents a had than and by the today, of and We issued which issued is December over significant of XXX year. pending, As more increase end last XX
the We position #X continue on This in noninvasive to and for leadership patent monitoring. focus organizations. X by been glucose documented expand position our has maintaining portfolio
We retained patent Patsnap research Group, firms. Capital and IP leading analytic
diligently our aspect property, of protect trade and secrets. we algorithms are intellectual trade another Our our secret
a scientific and of human work strategy. its advising and innovators established and clinical These and partners including development, technology distinguished research advancing experts the streams, have researchers, the comprised health. medical company on in also progress algorithm all strategic been technical board individuals advisory trial design device We've refinement, across publication company's and
established current our work. accelerate as in Board, Regulatory alongside they our which on Bringing help validate work They has XXXX. been and was board and experts industry us to Medical Advisory invaluable
align development and expenses clinical product to also to efforts our resources to the paid organization's our streamline as Lastly, better functions have critical off. such and
In from reduced per per month $X.X accelerating to our we addition to progress, $XXX,XXX burn roughly month. rate million
you is shows devices with lessons a took similar We're time. last period months. progress the throughout other a self-explanatory in we Now But to some we've especially short of proud it others able I'd with out of of level improvement. from X we this how before when jumping in improvement as impressive into graph. such been to compare time, achieve Bio-RFID it like long point the achieve to share learned the of want This those, to to the FDA-cleared I MARD it
do MARD device, compared blood Our a just a under with device to goal believe reference I is that. to and track we're XX% deliver to on
a new a We're worked to We next Part things. hard, lot, something achieved before. inventing our done never is has and we learned lot. of discovering we Moving that inventing new slide. been
we've institutes we discussions we and As we and experiments amplified experienced brought and space, hires development research and in-house with through intensified as stakeholders a our to the the relevant learned partnerships and marketplace. medical clinical and in as device in new in technology listened as expertise be such other global before players, learned. key launching more devices what detail presenting and We accomplished before our the FDA to needs
hyperglycemic topics across use glycemic devices range, We to people per collection especially like all Type more concentrated do to or following, accuracy current glucose range, learned successful to subsegments. in of We help is our X will requirements, expand front XX% the monitoring a hypo X These of the wider there be and diabetes in is of XX ranges. and is also our with XXX to us other normal regulatory conform which determine with scenarios the Type need than data deciliter. and still intended FDA. all More glucose data the to data work including megaliters in to
elements Patient physiological and set efforts diverse characteristics, data collection interference that our environment patients and of pigmentation, other factors. need skin to movement we skin a include the expand intense cause such hair sweat could of so presence more different thickness human and and with as they
other of such substances, tests have controlled the regulatory real-world Ultimate a technology. as conditions, pressure, currently and temperature, air humidity, approval understanding environmental interaction a conducted environment. human Our in laboratory requires with to noise us are deep
impact a medical diverse including steps with all X further its prediabetes. of diabetes ultimately These participants accuracy. device, they people more translate collection, involved its and All diabetes, into on may data Type but with with interfere signal are Type backgrounds, development X in work and the natural
characterization, sensor data algorithm controlled In equals we and the increase to demonstrated environment. refinement, performance, science data the Data algorithm, sensor better. a just have train it accuracy. as and in we better used repeatability stability of amount our gets More
Now of in applications we need outside the same laboratory. our to demonstrate real-world
are presenting technology. These validation, our to validate continue when we must regulatory our agency. external application institutes with And research the scientific to publications further additional critical
generalizability increase is our for of much platform is should past, This critical of any patient condition Medical intended devices a safe extremely by Bio-RFID streams and conditions patients technology that health but and in algorithm. physicians must we work its support to concept use. level success. the These of under maintain be and addressed accuracy haven't and accurate as and determined regardless that manage the our
with noninvasive has low around mission solutions to middle-income convenient, live in to of on lives are accessible be increased living According emphasize world X Diabetes Know focus the in been of world of XXX blood a forward. accessibility XXXX. the glucose a continues in difference diagnostic with there the in and countries. millions medical X in like people the Moving and and affordability. affordable, diabetes million adults first the monitoring. to by with Labs' making importance I'd people International diabetes and Federation, developing
for with device These increase A developed projected experiencing issues accessibility increase significantly than XXXX. East solution. free America. Middle has America of Africa, and projected therefore countries accelerated to increase, North rates are a XX% potential providing South a addressing higher growth areas from increase and consumable the by the and more Europe, XX% affordable projected XX% with user-friendly, XXX% facing and North XXXX and XX% respectively. an convenient These Central a are diabetes noninvasive and in Africa like
sensor to like important a that which combination our building. array X,XXX that the allows RF key platform wave powerful as such intervals emits these familiar that our energy the are everyone components IP remind field. as that spectrum The is The per potentially generator of the you million and megahertz of hour, us at research antennas to the novel we're protected. anything. can Most is enables captures And to features refer from Bio-RFID sensor with the collect frequency megahertz IP-protected and to to points But data also X,XXX spectrum the are approximately sweeps radio which signals, technology. measure a microwave X.X it's it core we Its elements sensor. sensor in of X.X makes and
lactate, to identify, ketones, potential alcohol expand to drugs. But has into blood being monitor other the it's and it used glucose. metabolized and biomarkers as now, such Right oxygen, measure
Bio-RFID the to Now platform.
measure technology that range data a for to can materials, leverages of designed and and technology We're electromagnetic is measure of The inorganic matter. combines energy sensor. molecules accurately not Our organic spectroscopy. approach a proprietary uniquely is algorithm. this analytes platform, a platform radio hardware powerful and multiple scientific processing term It and noninvasive a building compositions frequency wide identify with just
leveraging from bandwidth approach as radio electromagnetic Our waves. specific a to the microwave is others target spectrum spectroscopy we slightly in different from
machine low into any artificial to skin translates because or bill benchtop It its or accurate learning less factors. materials algorithms. which, can poking require form Bio-RFID and It it transmitters to of into real-time It X a needles power is potential expensive of integrated than is secret highly be through FDA-cleared be pain-free have models into with Xx current the wearable, factor doesn't form skin. options. intelligence or trade invasive doesn't agnostic. a combined the consumables, high Cutting-edge mobile variety
monitoring, believe is glucose how And it more Bio-RFID shown data a I we questions unable to a is noninvasive the which that XXX optical blood the This medical body, health of it's of enabler on representation glucose collects comprehensive to picture potential sensors target why and to powerful than different Bio-RFID different. potential is predictive from a a beyond diagnostic an make and could simple why tool. slide of enabling Bio-RFID lot the and transform diagnostics. has analytes important of achieve. get safely are
is targeting other achieve knowledge, Performance our a both by companies. depth proof technologies #XX-XXX-XXX, bandwidths technology than microwave titled approach. the This the being electromagnetic novel spectrum. To is and in " wave it patent Bio-RFID RFID's the transmission of only to Glucose other higher U.S. currently explored signal Sensor" radio allows
concentrations a venous stated in than tissue. on frequency and of and time the amount and by the collect FDA-cleared allows reading massive signals the enhanced data cellular decoupled patent market. the glucose antenna Bio-RFID As spectroscopy designs approaches differently across blood Radio capillary fluid, devices Bio-RFID available blood technology frequency currently glucose to interstitial by very technology real-time synchronization
penetrates than GX, Libre surface. into minimally such as readings the X field inch limited systems devices of current typically within body. are interstitial skin microfilaments energy FreeStyle and by Abbott only X/XX Labs' the the Dexcom the the of fluid more inch used to contrast, invasive Know Lab's In GX of
understanding and feature this monitoring monitoring. I available to blood a a very wearable focused devices CGMs strategy. have previously announced real-time It We've product slide before, portfolio market. similar provides glucose continuous seen our the X you glucose monitoring is the a of You've on assume UBand glucose to the user, currently in device. The good
diabetes manage all diabetes. glucose wearable for are not that their a continuous to know we device with monitoring But people looking
patient want levels. run replace don't spot KnowU provide can on-the-go the or glucose The sticks to the painful still of The rely simply inconvenient her expensive and We on. of is powered products, engineered checks alternative sticks. a a market. a final and they at finger convenient can Some price to these X blood research for cleared nonwearable currently point currently manufacturing his have for finger convenience lower much FDA easily materials KnowU and development the available should capable in of developing the bill is indicates delivering of we a device, and Gen full but which be the than product as options
why testing? simple need keep This that Some very keep do testing. makes you of me ask address Why to graph question. we to we it
to As the you which was few in MARD details go study we this our on our of experienced presentation, improvement A an algorithm's have above XX% a allowed data ago. included from a set increases, to has of I the a clear weeks This to covering MARD this direct XX.X%, in accuracy. read us website. of slide published been the appendix which
We're to with that more get level hopefully of This estimate devices, our combined new algorithm accuracy lower or prepare to have and we'll with process. collected our higher more figures. data we sensor, improve. procedure the raw will learning MARD performance is machine will with As of to standard a we Gen billions labels X undertake clinical confident can reference observations tens we testing lead
is a to artificial requires team intelligence collaborating and of learning. for development refinement. robust machine the engineering, algorithm As biological and in goal data changes factors. there accuracy core This diversity in machine variability expected learning industry-leading amount testing expanded we Bio-RFID's is approach At This massive data our of creator increase are the conditions, [Gempulse], sample resulting has size, toolkit accelerate to from the with collection. been data other of it
target. new is [LF study get planning already and the protocols. follows our a protocol this soon, from XX] previous different started next to We've which plan slightly underway for
be reference In using standard. data venous gold the to points, as click addition to using blood we'll CGMs
including diabetes the and prediabetes. diversity We our population will with increasing of people by also be
with Do page results visit and This great frequently newsletter. previous a these for results. our are up sign them as research website. as our we'll our publish we to validation is on reason soon have ready, As and that
Algorithm the and XXXX deliver of which for biodiversity and extended continue environmental process Our we've data a core goals aim exhausting the begun. which FDA, collection, parameters. with XX% at refinement socialization to focus strategy an design, smaller straightforward. we for more to manufacturing, on balance designed X to We'll glycemic very MARD, least and be XX% regulatory expanded Generation the range means are technology with already goal and under participants
blood core maintain continue patents. leadership noninvasive support support data In monitoring in capital and collection, data with IP and the that parallel, scope We'll growing our goals, we organization and design hardware required. areas expanding of glucose will affairs the our business needs science, as regulatory additional
last data science plan oriented and progress hardware and validation. continue We scientific made streams: significant aggressive place. we'll collection, refinement, in data have in months, and to sensor characterization core and on the an focus results-oriented our algorithm X work We've
development In our as our strategic patents addition, trade pending well property of as the issued, we portfolio, and development will secrets. in our intellectual continue codifying
see manuscripts from You shall team published. more with more also market activity our
FDA often will ultimately it to monitoring for obtain this when set clearance, It's the noninvasive forth shareholders commence As to go clinical difficult glucose exact we ask relates our and to to FDA device. blood dates. FDA clearance trials
developing and done We has never that technology are new before. inventing been
the data we clinical to needs continue product about collection addressed. must conditions, We we a expand undertaking before what market-ready be As accurate excellence of with learn clearance will for standard and FDA more application. trials achieve a to testing repeatable
takes clearance-related high share have but confidence FDA as soon rest you. we timelines, assured as in This time, them we'll that with
XXXX plan Know year the first market the significant vision deliver broader has of through truly far and thus change a noninvasive glucose diagnostics our to transform medical monitoring means. for to We Labs. are executing and been in the FDA-cleared device noninvasive investment
Conley, to will to our call Pete the Now turn review I'd financials. like who
